These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6128543)

  • 21. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of genetic factors in bladder cancer.
    Schulte PA
    Cancer Detect Prev; 1988; 11(3-6):379-88. PubMed ID: 3390858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carotenoids/vitamin C and smoking-related bladder cancer.
    Castelao JE; Yuan JM; Gago-Dominguez M; Skipper PL; Tannenbaum SR; Chan KK; Watson MA; Bell DA; Coetzee GA; Ross RK; Yu MC
    Int J Cancer; 2004 Jun; 110(3):417-23. PubMed ID: 15095308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased expression of ESCO1 is correlated with poor patient survival and its role in human bladder cancer.
    Zhang S; Li J; Zhou G; Mu D; Yan J; Xing J; Yao Z; Sheng H; Li D; Lv C; Sun B; Hong Q; Guo H
    Tumour Biol; 2016 Apr; 37(4):5165-70. PubMed ID: 26547586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.
    Hsieh FI; Pu YS; Chern HD; Hsu LI; Chiou HY; Chen CJ
    Br J Cancer; 1999 Oct; 81(3):537-41. PubMed ID: 10507782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bladder cancer risk from the perspective of genetic polymorphisms in the carcinogen metabolizing enzymes.
    Antonova O; Toncheva D; Grigorov E
    J BUON; 2015; 20(6):1397-406. PubMed ID: 26854433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
    Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
    Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility.
    Badawi AF; Stern SJ; Lang NP; Kadlubar FF
    Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population.
    Rouissi K; Ouerhani S; Marrakchi R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
    Cancer Genet Cytogenet; 2009 Apr; 190(2):101-7. PubMed ID: 19380028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highlight report: N-acetyltransferase 2 and urinary bladder cancer risk.
    Blaszkewicz M
    Arch Toxicol; 2017 Sep; 91(9):3205-3206. PubMed ID: 28577040
    [No Abstract]   [Full Text] [Related]  

  • 33. [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls].
    Sone M
    Hinyokika Kiyo; 1986 Aug; 32(8):1085-92. PubMed ID: 3788733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
    Selinski S; Gerullis H; Otto T; Roth E; Volkert F; Ovsiannikov D; Salem J; Moormann O; Geis BC; Niedner H; Blaszkewicz M; Hengstler JG; Golka K
    Eur Urol; 2017 Jun; 71(6):994-995. PubMed ID: 28040354
    [No Abstract]   [Full Text] [Related]  

  • 35. Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2.
    Gago-Dominguez M; Bell DA; Watson MA; Yuan JM; Castelao JE; Hein DW; Chan KK; Coetzee GA; Ross RK; Yu MC
    Carcinogenesis; 2003 Mar; 24(3):483-9. PubMed ID: 12663508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans.
    Kadlubar FF
    Drug Metab Rev; 1994; 26(1-2):37-46. PubMed ID: 8082575
    [No Abstract]   [Full Text] [Related]  

  • 37. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
    McGrath M; Michaud D; De Vivo I
    BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Relationship between genetic polymorphism of NAT2 and susceptibility to urinary bladder cancer].
    Hao GY; Zhang WD; Chen YH; Zhang DX; Zhang YH
    Zhonghua Zhong Liu Za Zhi; 2004 May; 26(5):283-6. PubMed ID: 15312364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphic expression of acetyl coenzyme A-dependent arylamine N-acetyltransferase and acetyl coenzyme A-dependent O-acetyltransferase-mediated activation of N-hydroxyarylamines by human bladder cytosol.
    Kirlin WG; Trinidad A; Yerokun T; Ogolla F; Ferguson RJ; Andrews AF; Brady PK; Hein DW
    Cancer Res; 1989 May; 49(9):2448-54. PubMed ID: 2784998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?
    Murta-Nascimento C; Silverman DT; Kogevinas M; García-Closas M; Rothman N; Tardón A; García-Closas R; Serra C; Carrato A; Villanueva C; Dosemeci M; Real FX; Malats N
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1595-600. PubMed ID: 17684133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.